Waldenström's macroglobulinemia differential diagnosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mirdula Sharma, MBBS [2]
|
Waldenström's macroglobulinemia Microchapters |
|
Differentiating Waldenström's macroglobulinemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Waldenström's macroglobulinemia differential diagnosis On the Web |
|
American Roentgen Ray Society Images of Waldenström's macroglobulinemia differential diagnosis |
|
FDA on Waldenström's macroglobulinemia differential diagnosis |
|
CDC on Waldenström's macroglobulinemia differential diagnosis |
|
Waldenström's macroglobulinemia differential diagnosis in the news |
|
Blogs on Waldenström's macroglobulinemia differential diagnosis |
|
Directions to Hospitals Treating Waldenström's macroglobulinemia |
|
Risk calculators and risk factors for Waldenström's macroglobulinemia differential diagnosis |
Waldenström's macroglobulinemia must be differentiated from other B cell lymphoid neoplasms including:
- Always express CD5, usually CD23 positive[1]
- Express bright surface IgM, CD20 and other B-cell antigens (CD19, CD22, CD79a, FMC7)[1]
- Express CD138, CD38, CD79a, and VS38c and CD56(70%)[1]
- Presence of Plasmacytic cell infiltration of bone marrow, osteolytic lesions and renal insufficiency[2]
- Translocation involving chromosome 11 (t 11;14)
- Marginal zone lymphoma:
References=
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma. UpToDate (2015)http://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-lymphoplasmacytic-lymphoma?source=see_link§ionName=PATHOGENESIS&anchor=H198194648#H198194648 Accessed on November 9, 2015
- ↑ 2.0 2.1 2.2 2.3 Sahin I, Leblebjian H, Treon SP, Ghobrial IM (2014). "Waldenström macroglobulinemia: from biology to treatment". Expert Rev Hematol. 7 (1): 157–68. doi:10.1586/17474086.2014.871494. PMID 24405328.